Orchestra BioMed will hold an R&D Day on November 12, 2026, in New York City and via webcast to discuss clinical insights and development plans for its AVIM Therapy and Virtue SAB products. The event will feature company leaders and leading cardiologists reviewing the clinical burden of hypertension and coronary artery disease, pivotal trial updates, and upcoming milestones. AVIM Therapy targets uncontrolled hypertension in pacemaker patients, backed by a Medtronic partnership, while Virtue SAB addresses coronary restenosis with a novel drug delivery system. Both therapies have FDA Breakthrough Device Designations and represent large market opportunities.
As of Oct 22, 2026 19:13 WIB, Medtronic PLC (MDT), a key partner in Orchestra BioMed's AVIM Therapy, trades at USD 93.12 on Pluang with a slight 1-day increase of 0.10%. The stock shows a high market cap of $119.00 billion and an enterprise value of $138.33 billion, reflecting its significant presence in the health sector. Notably, Pluang investors have predominantly sold MDT shares recently, with 93% of order activity being sell orders at this time.
